12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies

Acute Aortic Regurgitation (AR): Etiology and Pathophysiology

Acute severe aortic regurgitation is a life-threatening cardiovascular emergency requiring immediate recognition, precise pharmacological stabilization, and rapid surgical consultation. While chronic aortic regurgitation allows the left ventricle months to years to develop eccentric hypertrophy and dilate to accommodate large regurgitant volumes without high intracavitary pressures, acute aortic regurgitation delivers a sudden massive diastolic volume into a normal-sized, non-compliant left ventricle.

Etiological Spectrum

The primary etiologies of acute aortic regurgitation in the intensive care unit include:

1. Acute Stanford Type A Aortic Dissection: Retrograde extension of an intimal tear into the aortic root disrupts the commissural attachments of the aortic valve cusps, causes leaflet prolapse, or induces annular dilation, resulting in acute, massive regurgitation.
2. Infective Endocarditis (IE): Rapid vegetative destruction, cusp perforation, flail aortic leaflet, or perivalvular annular abscess extending through the fibrous skeleton.
3. Blunt Thoracic Trauma: High-energy deceleration injury causing sudden avulsion or tear of an aortic cusp.
4. Iatrogenic / Transcatheter Complications: Cusp injury or severe paravalvular regurgitation following transcatheter aortic valve replacement (TAVR), balloon aortic valvuloplasty, or transcatheter structural heart interventions.

The Hemodynamic Crisis of Acute Aortic Regurgitation

In acute AR, during ventricular diastole, blood flows retrogradely from the high-pressure aorta directly into the left ventricle alongside antegrade flow entering from the left atrium. Because the non-dilated left ventricle has steep diastolic compliance ($dP/dV$), left ventricular end-diastolic volume (LVEDV) increases only modestly, but left ventricular end-diastolic pressure (LVEDP) surges catastrophically, often reaching $30\text{ to }50\text{ mmHg}$ within a few cardiac cycles.

This extreme elevation in LVEDP produces two immediate pathophysiological consequences:

• Severe Forward Hypoperfusion: Forward effective stroke volume ($SV_{\text{forward}} = SV_{\text{total}} - SV_{\text{regurgitant}}$) drops precipitously, producing cardiogenic shock, profound lactic acidosis, and organ hypoperfusion.
• Acute Hydrostatic Pulmonary Edema: When LVEDP exceeds left atrial pressure, backward transmission of pressure triggers extreme pulmonary venous hypertension and severe flash pulmonary edema.

Premature Mitral Valve Closure and Auscultatory Hallmarks

The pathognomonic physical and echocardiographic finding in acute severe AR is premature diastolic closure of the mitral valve. Because LVEDP rises so rapidly in mid-to-late diastole, it quickly exceeds left atrial pressure before electrical ventricular systole begins. The pressure gradient across the mitral valve reverses in diastole, forcing the mitral leaflets closed prior to the onset of the QRS complex on the electrocardiogram:

• On M-mode echocardiography, premature coaptation of the anterior and posterior mitral valve leaflets in mid-diastole (well before the QRS) is a direct marker of life-threateningly elevated LVEDP.
• On auscultation, the first heart sound ($S_1$) is markedly soft or completely absent because the mitral valve has already snapped shut in diastole and cannot close with normal systolic velocity.
• The Diastolic Murmur: Unlike the loud, blowing, holodiastolic decrescendo murmur of chronic AR, the murmur of acute AR is short, soft, low-pitched, and early diastolic. As LVEDP surges to meet aortic diastolic pressure, the diastolic pressure gradient between the aorta and left ventricle rapidly equilibrates to near zero in mid-diastole, causing regurgitant flow to cease well before systole.

Absence of Chronic Peripheral Signs

In chronic AR, a large total stroke volume ejected into a dilated, compliant arterial tree produces a wide pulse pressure (e.g., $160/40\text{ mmHg}$) and famous peripheral eponyms (water-hammer Corrigan's pulse, Quincke's capillary pulsations, Duroziez's sign, Hill's sign). In acute AR, forward stroke volume is severely curtailed, peripheral vasoconstriction is intense, and aortic diastolic pressure rapidly equilibrates with elevated LVEDP. Consequently:

• The pulse pressure is normal or narrow (e.g., $95/70\text{ mmHg}$).
• All classic peripheral eponyms of chronic AR are strictly ABSENT.

---

Hemodynamic Management and Absolute Contraindications in Acute AR

Recognizing acute aortic regurgitation requires adhering to strict pharmacological and mechanical rules while mobilizing cardiac surgery:

The Lethal Hazard of Intra-Aortic Balloon Counterpulsation (IABP)

Avoidance of Beta-Blockers

In acute AR, effective forward stroke volume is critically restricted. To preserve cardiac output ($CO = HR \times SV$), the patient's autonomic nervous system generates a robust, compensatory sinus tachycardia. A higher heart rate shortens the duration of diastole, which directly limits the time available for regurgitant volume to flow back into the left ventricle per beat.

Administering beta-blockers (e.g., metoprolol, esmolol, labetalol) eliminates this vital compensatory tachycardia. Prolonging diastole allows a massive increase in regurgitant volume per cardiac cycle, driving LVEDP even higher and precipitating immediate asystole or pulseless electrical activity (PEA).

Medical Stabilization and Urgent Surgical Timing

Medical management serves purely as a brief bridge to the operating room:

• Vasodilators: Intravenous sodium nitroprusside reduces systemic vascular resistance, promoting forward stroke volume and reducing the regurgitant fraction. It is safe only if systemic arterial pressure can be maintained (SBP > 90-100 mmHg).
• Inotropes: Intravenous dobutamine or dopamine augments forward contractility and provides mild chronotropic and vasodilatory properties to maintain forward cardiac output.
• Vasopressors: If profound shock is present, norepinephrine can maintain perfusion pressure, but excessive vasoconstriction increases afterload and worsens regurgitant fraction; it should be titrated cautiously.
• Definitive Surgery: Emergent open surgical aortic valve replacement (AVR) or root replacement is the only definitive therapy and must not be delayed.

---

Acute Mitral Regurgitation (MR): Mechanics and Management

Acute severe mitral regurgitation results from an abrupt structural disruption of the mitral valve apparatus, which consists of the leaflets, annulus, chordae tendineae, and papillary muscles.

Mechanisms and Vascular Anatomy of Papillary Muscle Rupture

Acute MR in the ICU commonly arises from:

1. Acute Myocardial Infarction with Papillary Muscle Rupture: Occurs typically $2\text{ to }7\text{ days}$ following acute myocardial infarction. The posteromedial papillary muscle ruptures 6 to 10 times more frequently than the anterolateral papillary muscle:
   • Posteromedial Papillary Muscle: Has a single, solitary blood supply provided entirely by the posterior descending artery (PDA; branching from the right coronary artery [RCA] in $85\%$ of patients, or the left circumflex [LCx] in $15\%$). Ischemia or occlusion of the PDA results in transmural infarction and catastrophic rupture.
   • Anterolateral Papillary Muscle: Possesses a dual blood supply from both the left anterior descending (LAD) diagonal branches and the LCx obtuse marginal branches, rendering it significantly more resistant to complete ischemic necrosis.
2. Infective Endocarditis: Destruction of the mitral leaflets, perforation, or chordal rupture secondary to active infection.
3. Degenerative / Spontaneous Chordal Rupture: Sudden rupture of primary chordae in patients with underlying myxomatous valve disease (mitral valve prolapse).
4. Blunt Chest Trauma: Rupture of chordae or papillary muscles from sudden compressive deceleration.

Pathophysiology and Giant "v" Waves

In acute MR, a large regurgitant volume is suddenly ejected during ventricular systole backwards into a normal-sized, non-compliant left atrium. The left atrial volume-pressure curve is steep:

• Acute systolic volume overload creates a towering systolic pressure peak in the left atrium, reflected on pulmonary artery wedge pressure (PAWP) tracings as giant regurgitant "v" waves (often peaking at $40\text{ to }70\text{ mmHg}$).
• These giant "v" waves are transmitted backward directly into the pulmonary venous and capillary beds, causing rapid, severe hydrostatic pulmonary edema.
• On auscultation, the murmur of acute MR is often deceptive: it is frequently early systolic, soft, decrescendo, and terminates before $S_2$. This occurs because late in systole, the pressure in the stiff, non-compliant left atrium rapidly approaches left ventricular systolic pressure, eliminating the pressure gradient driving regurgitation.

Medical and Mechanical Circulatory Support

Unlike acute aortic regurgitation, acute mitral regurgitation responds exceptionally well to mechanical circulatory support:

• Intra-Aortic Balloon Counterpulsation (IABP) IS INDICATED: In acute MR, the IABP is a premier bridging modality. Rapid balloon deflation immediately prior to ventricular systole creates an afterload vacuum in the ascending aorta, markedly lowering LV afterload. This dramatically favors forward flow into the aorta, slashes the regurgitant fraction flowing backward into the left atrium, shrinks the giant "v" waves, and resolves pulmonary edema. Diastolic balloon inflation also improves coronary perfusion to the ischemic myocardium.
• Vasodilators: Intravenous sodium nitroprusside is the preferred pharmacologic agent, reducing afterload and increasing forward cardiac output.
• Definitive Surgery: Emergent surgical mitral valve repair or replacement is mandatory.

---

Prosthetic Valve Emergencies: Thrombosis, Endocarditis & Paravalvular Leaks

Patients with prosthetic heart valves (mechanical or bioprosthetic) who present to the ICU with acute dyspnea, shock, or systemic embolization must be evaluated for three life-threatening complications.

Mechanical and Bioprosthetic Valve Thrombosis

Prosthetic valve thrombosis (PVT) is most frequent with mechanical valves (annual incidence $0.3\%\text{ to }1.3\%$ in left-sided valves, up to $8\%$ in tricuspid valves), especially in the setting of subtherapeutic anticoagulation (international normalized ratio [INR] $< 2.0-2.5$).

• Clinical Presentation: Acute pulmonary edema, cardiogenic shock, muffled or absent prosthetic closing clicks, new regurgitant or obstructive murmur, or systemic thromboembolic stroke.
• Multimodal Diagnostic Evaluation:
  1. Transthoracic Echocardiography (TTE): First-line imaging to detect elevated peak and mean transvalvular gradients, decreased effective orifice area (EOA), and right/left ventricular dysfunction.
  2. Transesophageal Echocardiography (TEE): Essential for left-sided prosthetic valves. Overcomes acoustic shadowing from mechanical rings to visualize thrombus size, location (atrial vs. ventricular aspect), mobility, and extension.
  3. Cine-Fluoroscopy: The gold standard modality for assessing mechanical disc or leaflet motion. It provides real-time radiographic visualization of leaflet opening and closing angles, readily identifying restricted or immobile tilting discs that ultrasound may miss.

Management of Left-Sided Mechanical Valve Thrombosis

Management is dictated by thrombus size, functional class, and surgical risk:

1. Emergent Surgery (Valve Replacement or Thrombectomy): Indicated for patients with:
   • Obstructive thrombosis with cardiogenic shock (NYHA Class IV).
   • Large thrombus burden (thrombus area $\ge 0.8\text{ cm}^2$ or mobile length $\ge 10\text{ mm}$ on TEE), due to excessive risk of cerebral embolization with thrombolysis ($> 15\%$).
   • Absolute contraindications to fibrinolytic therapy.
   • Failed fibrinolysis.
2. Low-Dose, Slow-Infusion Fibrinolysis Protocol:
   • Historical rapid high-dose protocols (e.g., streptokinase or tPA $100\text{ mg}$ over 2 hours) carried unacceptable rates of major bleeding ($> 10\%$) and fatal intracranial hemorrhage.
   • Modern Protocols (Özkan and colleagues): The TROIA registry used low-dose tPA $25\text{ mg}$ over 6 hours without a bolus, and the PROMETEE study used an ultraslow $25\text{ mg}$ infusion over 25 hours without a bolus; in both, the dose was repeated after TEE reassessment until the thrombus resolved (PROMETEE allowed up to eight sessions), with unfractionated heparin between sessions. Success rates were about 90% with low rates of major complications, and the ultraslow regimen had the fewest.
   • Guideline Positions: The 2020 ACC/AHA guideline recommends urgent treatment with either slow-infusion low-dose fibrinolysis or emergency surgery for symptomatic obstructive left-sided mechanical valve thrombosis, choosing by thrombus size, surgical risk, and local expertise. The 2021 ESC/EACTS guideline favors urgent surgery for obstructive left-sided thrombosis in patients without serious comorbidity and reserves fibrinolysis for patients at high surgical risk, when surgery is unavailable, or for right-sided prosthetic thrombosis.
   • Not to Confuse: PROACT is the On-X mechanical valve anticoagulation trial (lower INR targets), not a fibrinolysis regimen.

Prosthetic Valve Endocarditis (PVE)

PVE accounts for $20\%\text{ to }30\%$ of all infective endocarditis cases and carries a hospital mortality of $30\%\text{ to }50\%$:

• Early PVE ($< 1\text{ year}$ post-surgery): Primarily acquired perioperatively in the hospital. The dominant pathogen is methicillin-resistant Staphylococcus epidermidis (MRSE), followed by Staphylococcus aureus, Gram-negative bacilli, and fungi (Candida). MRSE forms an impenetrable biofilm on foreign material, frequently invading the sewing ring and perivalvular annular tissue to produce ring abscesses, pseudoaneurysms, and valve dehiscence.
• Late PVE ($> 1\text{ year}$ post-surgery): Acquired in the community. Microbiology mirrors native valve endocarditis: viridans group streptococci, Enterococcus faecalis, and community-acquired S. aureus.
• Indications for Urgent Surgical Intervention in PVE:
  1. Severe heart failure or cardiogenic shock refractory to medical therapy.
  2. Perivalvular extension: annular abscess, pericardial fistula, new atrioventricular block, or pseudoaneurysm.
  3. Persistent bacteremia or positive blood cultures $\ge 5-7\text{ days}$ despite targeted antimicrobial therapy.
  4. Infection caused by multidrug-resistant pathogens or fungi (Candida, Aspergillus).
  5. Large mobile vegetations ($> 10\text{ mm}$) associated with embolic events.
  6. Significant prosthetic valve dehiscence or severe paravalvular regurgitation.

Paravalvular Leak (PVL)

Paravalvular leaks occur when tissue retraction, suture rupture, annular calcification, or endocarditis creates a channel between the prosthetic sewing ring and surrounding cardiac tissue:

• Clinical Manifestations: Heart failure from volume overload, and/or severe Coombs-negative mechanical hemolytic anemia caused by high-velocity shear stress tearing erythrocytes across the narrow defect. Diagnostic labs show elevated serum lactate dehydrogenase ($> 1,000\text{ U/L}$), undetectable haptoglobin, reticulocytosis, and peripheral blood smear showing numerous schistocytes.
• Management: 3D transesophageal echocardiography precisely maps the defect. Surgical re-anchoring or valve re-replacement is indicated for large leaks or active infection. In patients with prohibitive surgical risk, percutaneous transcatheter closure using dedicated vascular plug occluders (e.g., Amplatzer plugs) is the preferred alternative.

---

Severe Aortic Stenosis in the Critically Ill Patient

A stenotic aortic valve creates a fixed outflow obstruction. The hypertrophied left ventricle depends on preload, sinus rhythm (atrial kick), and diastolic coronary perfusion pressure.

• Severity markers (echocardiography): peak velocity at least $4\text{ m/s}$, mean gradient at least $40\text{ mmHg}$, or valve area at most $1.0\text{ cm}^2$. A low-flow, low-gradient pattern (area at most $1.0\text{ cm}^2$ with a mean gradient below $40\text{ mmHg}$ and reduced ejection fraction) needs dobutamine stress echocardiography or a CT calcium score to separate true severe stenosis from pseudostenosis.
• Hypotension is poorly tolerated: falling diastolic pressure cuts coronary flow to a thick ventricle, which worsens ischemia and output (a spiral). Treat hypotension early with an alpha-agonist (phenylephrine or norepinephrine).
• Avoid: large preload reduction (aggressive diuresis, nitrates, high-dose sedatives that cause venodilation), sudden afterload reduction, and tachycardia. Restore sinus rhythm promptly; new atrial fibrillation with hypotension needs cardioversion.
• Decompensated aortic stenosis with low output: inotropes are a short bridge. In older single-center data, carefully titrated nitroprusside guided by a pulmonary artery catheter improved output in selected patients with severe left ventricular dysfunction and high systemic resistance. Definitive relief, with urgent transcatheter aortic valve replacement (TAVR) or balloon aortic valvuloplasty as a bridge, is the goal.
• Procedures and sedation: induction and positive-pressure ventilation can precipitate collapse. Prepare vasopressors before intubation and choose hemodynamically neutral agents.

Mitral Stenosis

• Pressure in the left atrium is set by flow across the valve and diastolic filling time. Tachycardia shortens diastole, raises left atrial pressure, and causes pulmonary edema, which is why decompensation often follows new atrial fibrillation, fever, anemia, sepsis, or pregnancy.
• Management: rate control (beta-blocker or nondihydropyridine calcium-channel blocker) to lengthen diastole, diuretics for congestion, and cardioversion for unstable atrial fibrillation. Patients with rheumatic mitral stenosis and atrial fibrillation need warfarin (DOACs are not recommended in moderate-to-severe rheumatic mitral stenosis). Percutaneous balloon mitral commissurotomy, when the valve is suitable, or surgery is definitive.

Tricuspid and Right-Sided Valve Emergencies

• Tricuspid valve endocarditis (commonly Staphylococcus aureus in people who inject drugs, or device-related) presents with fever, bacteremia, and septic pulmonary emboli (multiple peripheral cavitating nodules).
• Severe tricuspid regurgitation causes venous congestion, hepatic congestion, and a pulsatile liver. It frequently reflects right ventricular dilation from pulmonary hypertension or pacemaker leads.
• Surgery for right-sided endocarditis is considered for persistent bacteremia despite appropriate therapy, very large vegetations with recurrent emboli, or right heart failure that does not respond to medical therapy.